Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients

被引:262
作者
Tisdale, James E. [1 ,2 ]
Jaynes, Heather A. [1 ]
Kingery, Joanna R. [3 ]
Mourad, Noha A. [1 ]
Trujillo, Tate N. [3 ]
Overholser, Brian R. [1 ,2 ]
Kovacs, Richard J. [2 ,4 ]
机构
[1] Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA
[3] Indiana Univ, Hlth Methodist Hosp, Dept Pharm, Indianapolis, IN 46204 USA
[4] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2013年 / 6卷 / 04期
基金
美国国家卫生研究院;
关键词
electrocardiography; predictors; QT interval; risk factors; torsades de pointes; TORSADE-DE-POINTES; LONG-QT; PROLONGING DRUGS; QUINIDINE; CARE; PREVALENCE;
D O I
10.1161/CIRCOUTCOMES.113.000152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Identifying hospitalized patients at risk for QT interval prolongation could lead to interventions to reduce the risk of torsades de pointes. Our objective was to develop and validate a risk score for QT prolongation in hospitalized patients. Methods and Results In this study, in a single tertiary care institution, consecutive patients (n=900) admitted to cardiac care units comprised the risk score development group. The score was then applied to 300 additional patients in a validation group. Corrected QT (QT(c)) interval prolongation (defined as QT(c)>500 ms or an increase of >60 ms from baseline) occurred in 274 (30.4%) and 90 (30.0%) patients in the development group and validation group, respectively. Independent predictors of QT(c) prolongation included the following: female (odds ratio, 1.5; 95% confidence interval, 1.1-2.0), diagnosis of myocardial infarction (2.4 [1.6-3.9]), septic shock (2.7 [1.5-4.8]), left ventricular dysfunction (2.7 [1.6-5.0]), administration of a QT-prolonging drug (2.8 [2.0-4.0]), 2 QT-prolonging drugs (2.6 [1.9-5.6]), or loop diuretic (1.4 [1.0-2.0]), age >68 years (1.3 [1.0-1.9]), serum K+ <3.5 mEq/L (2.1 [1.5-2.9]), and admitting QT(c) >450 ms (2.3; confidence interval [1.6-3.2]). Risk scores were developed by assigning points based on log odds ratios. Low-, moderate-, and high-risk ranges of 0 to 6, 7 to 10, and 11 to 21 points, respectively, best predicted QT(c) prolongation (C statistic=0.823). A high-risk score 11 was associated with sensitivity=0.74, specificity=0.77, positive predictive value=0.79, and negative predictive value=0.76. In the validation group, the incidences of QT(c) prolongation were 15% (low risk); 37% (moderate risk); and 73% (high risk). Conclusions A risk score using easily obtainable clinical variables predicts patients at highest risk for QT(c) interval prolongation and may be useful in guiding monitoring and treatment decisions.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 50 条
  • [31] QT interval prolongation in patients with acute ischemic stroke: a report in northwest China
    Wu, Jine
    Nizhamuding, Dilimulati
    Liu, Peng
    Jiang, Yongrong
    Qiang, Hua
    Sun, Chaofeng
    Dai, Chongliang
    Yin, Yanrong
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (12) : 5986 - 5995
  • [32] Percentile categorization of QT interval as an approach for identifying adult patients at risk for cardiovascular death
    Mohebi, Reza
    Jehan, Ayesha
    Grober, Aaron
    Froelicher, Victor
    [J]. HEART RHYTHM, 2017, 14 (08) : 1210 - 1216
  • [33] QT interval dynamics predict mortality in high-risk patients after myocardial infarction
    Hintze, U
    Vach, W
    Burchardt, H
    Videbæk, J
    Moller, M
    [J]. SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2002, 36 (05) : 276 - 281
  • [34] QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis
    Trevisani, Franco
    Di Micoli, Antonio
    Zambruni, Andrea
    Biselli, Maurizio
    Santi, Valentina
    Erroi, Virginia
    Lenzi, Barbara
    Caraceni, Paolo
    Domenicali, Marco
    Cavazza, Mario
    Bernardi, Mauro
    [J]. LIVER INTERNATIONAL, 2012, 32 (10) : 1510 - 1515
  • [35] QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin
    Chorin, Ehud
    Wadhwani, Lalit
    Magnani, Silvia
    Dai, Matthew
    Shulman, Eric
    Nadeau-Routhier, Charles
    Knotts, Robert
    Bar-Cohen, Roi
    Kogan, Edward
    Barbhaiya, Chirag
    Aizer, Anthony
    Holmes, Douglas
    Bernstein, Scott
    Spinelli, Michael
    Park, David S.
    Stefano, Carugo
    Chinitz, Larry A.
    Jankelson, Lior
    [J]. HEART RHYTHM, 2020, 17 (09) : 1425 - 1433
  • [36] QT interval prolongation among patients treated with angiogenesis inhibitors
    Ederhy, Stephane
    Cohen, Ariel
    Dufaitre, Ghislaine
    Izzedine, Hassan
    Massard, Christophe
    Meuleman, Catherine
    Besse, Benjamin
    Berthelot, Emmanuelle
    Boccara, Franck
    Soria, Jean-Charles
    [J]. TARGETED ONCOLOGY, 2009, 4 (02) : 89 - 97
  • [37] Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?
    Buss, Vera H.
    Lee, Kayla
    Naunton, Mark
    Peterson, Gregory M.
    Kosari, Sam
    [J]. JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [38] Appraise QT interval prolongation risk with collected telemetry ECG data
    CHENG Xing
    [J]. 中国药理学与毒理学杂志, 2013, (03) : 573 - 574
  • [39] Towards limiting QT interval prolongation and arrhythmia risk in citalopram use
    Zhang, Yihong
    Baranchuk, Adrian
    Hancox, Jules C.
    [J]. CARDIOLOGY JOURNAL, 2014, 21 (05) : 454 - 457
  • [40] Editorial: Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond
    Grandi, Eleonora
    Morotti, Stefano
    Pueyo, Esther
    Rodriguez, Blanca
    [J]. FRONTIERS IN PHYSIOLOGY, 2018, 9